Introduction {#s1}
============

Glutathione (GSH) is the most abundant antioxidant capable of providing reducing equivalents and it also serves as a versatile nucleophilic cofactor in a wide spectrum of metabolic reactions in aerobic organisms ([@bib48]; [@bib62]). While some cells are capable of employing extracellular GSH, the utilization of extracellular GSH plays a minor role in regulating GSH homeostasis, since the extracellular levels of GSH are normally three orders of magnitude lower than intracellular GSH concentrations, which are usually in the millimolar range ([@bib48]; [@bib62]; [@bib82]; [@bib37]; [@bib29]; [@bib5]; [@bib66]; [@bib76]). Hence, cellular GSH content is largely determined by intracellular production through de novo synthesis, a process mediated by two ATP-dependent ligases, glutamate-cysteine ligase (GCL) and glutathione synthase (GS), as well as through regeneration of GSH from GSSG, a process catalyzed by glutathione disulfide reductase (GSR) ([@bib62]; [@bib54]). In the process of de novo synthesis, GCL, a heterodimer of a catalytic subunit (GCLC) and a modifier subunit (GCLM), catalyzes the first and rate-limiting step to form the dipeptide γ-glutamylcysteine (γ-GC) from cysteine and glutamate ([@bib27]; [@bib10]). After the initial step, GS catalyzes the formation of GSH by ligating γ-GC with glycine. As such, GSH synthesis is determined by the availability of its constituent amino acids, cysteine, glycine and glutamate, which intersects with glucose and glutamine metabolic pathways and reflects the overall metabolic status in the cell. In particular, glutamine catabolism may coordinate with de novo GSH synthesis by promoting cysteine uptake and providing glutamate, an immediate product of glutamine after deamination ([@bib3]; [@bib35]; [@bib33]). However, it remains unknown the extent to which de novo synthesis versus recycling of GSSG contributes to GSH homeostasis in T cells and how the perturbation of GSH homeostasis impacts T cell differentiation.

The regulation of metabolic pathways is tightly linked with T cell activation, differentiation, and immune functions ([@bib108]; [@bib79]; [@bib74]; [@bib77]; [@bib57]; [@bib9]; [@bib117]; [@bib25]; [@bib111]). We and others have shown that activation of T cells leads to a significant enhancement of aerobic glycolysis but a suppression of mitochondria-dependent fatty acid oxidation (FAO) ([@bib107]; [@bib28]; [@bib39]; [@bib95]). Following the initial growth stage of T cell activation, FAO fuels and drives induced CD4^+^ regulatory T (Treg) cell differentiation ([@bib95]; [@bib63]). In contrast, a persistent glycolytic program is engaged not only during the initial growth phase of T cell activation but also throughout the differentiation of other CD4^+^T helper (T~H~) cells and CD8^+^ cytotoxic T (CTL) cells ([@bib95]; [@bib63]; [@bib26]). However, oxygen consumption is also dramatically elevated in active T cells since heightened glutamine catabolism via mitochondria-dependent oxidation following T cell activation fuels oxidative phosphorylation (OXPHOS) by providing α-ketoglutarate (α-KG), an anaplerotic substrate of the tricarboxylic acid cycle (TCA cycle) ([@bib107]; [@bib93]; [@bib42]). OXPHOS in mitochondria generates ATP through the electron transport chain (ETC) and also produces reactive oxygen species (ROS) as byproducts, rendering mitochondria a major source of intracellular ROS. Superoxide anion (O~2~^•−^), the 'primary' ROS derived from mitochondrial ETC, is converted to hydrogen peroxide (H~2~O~2~) by spontaneous and enzymatic processes, whereupon H~2~O~2~ freely diffuses into cytosol and functions as a redox signaling molecule to elicit a diverse array of cellular responses, the spectrum of which depends on the level of ROS ([@bib93]; [@bib42]; [@bib70]; [@bib91]). A fine-tuned balance between ROS generation and antioxidant capacity ensures physiological levels of intracellular ROS, which are required for driving essential signaling events to support T cell-mediated immune responses ([@bib111]; [@bib71]; [@bib43]; [@bib96]; [@bib87]). Accordingly, oxidative stress, occurring when ROS generation exceeds the capacity of antioxidants, dampens essential cellular processes and functions of T cells. In innate immune cells, ROS are effector molecules that are capable of directly killing pathogens as well as act as redox signaling molecules that modulate a wide range of innate immune responses ([@bib91]; [@bib65]; [@bib73]). Accumulating evidence has shown that ROS production is induced following T cell activation and is required for driving T cell activation and proliferation ([@bib93]; [@bib42]). Also, T~H~17 cells are more sensitive to the damaging effects of ROS than are T~reg~ cells ([@bib30]). A recent study demonstrated a critical role for GSH biosynthesis in fine-tuning this process by maintaining ROS hemostasis and regulating Myc-dependent T cell metabolic reprogramming during T cell activation ([@bib58]; [@bib46]). Little information exists, however, on whether and how T cell metabolic programs modulate T cell GSH biosynthesis and ROS homeostasis.

Here, we report a critical role for de novo GSH synthesis but not recycling of GSSG in modulating ROS homeostasis and T cell differentiation. Heightened glutamine catabolism during T~H~17 differentiation provides glutamate to support de novo GSH synthesis and suppresses oxidative stress. Genetic ablation of de novo synthesis of GSH but not regeneration of GSH from GSSG leads to the augmentation of ROS, dampening T~H~17 differentiation while enhancing T~reg~ cell differentiation. Moreover, we found that dimethyl fumarate, an FDA approved drug (BG-12/Tecfidera) for multiple sclerosis, suppresses T~H~17 differentiation by augmenting intracellular ROS. Combining pharmacological and genetic approaches, our studies implicate the GSH-ROS axis as a metabolic checkpoint coordinating glutamine catabolism and T cell signaling to direct T cell differentiation.

Results {#s2}
=======

De novo synthesis but not recycling of GSSG is required for producing GSH and suppressing ROS upon TCR stimulation {#s2-1}
------------------------------------------------------------------------------------------------------------------

T cell activation is associated with enhanced GSH and ROS production ([Figure 1---figure supplement 1A and B](#fig1s1){ref-type="fig"}) ([@bib93]; [@bib42]; [@bib58]). GSH can be regenerated through recycling of glutathione disulfide (GSSG) or synthesized de novo from glutamate, cysteine and glycine ([Figure 1A](#fig1){ref-type="fig"}). GSH regeneration is mediated by glutathione-disulfide reductase (GSR), whereas de novo synthesis is composed of two steps catalyzed by glutamine-cysteine ligase (GCL), a heterodimer of a catalytic subunit (GCLC) and a modulatory subunit (GCLM), and glutathione synthase (GS), respectively ([Figure 1A](#fig1){ref-type="fig"}). Thus, we examined the expression of the above key enzymes following T cell activation. Real time quantitative PCR (qPCR) analysis revealed a time-dependent up-regulation of mRNAs encoding these metabolic enzymes in T cells following activation ([Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}).

![De novo synthesis but not recycling of GSSG is required for producing GSH and fine-tuning ROS upon TCR stimulation.\
(**A**) Diagram of GSH biosynthesis, with metabolic pathways highlighted in red and enzymes highlighted in blue. (**B**) Naive CD4^+^T cells from WT and *Gclm* KO (left), or WT (*CD4-Cre-, Gclc^fl/fl^*) and *Gclc* KO (*CD4-Cre+, Gclc^fl/fl^*, (middle), or WT and *Gsr* KO (right) were activated by plate-bound anti-CD3 plus anti-CD28 for 24 hr, followed by the measurement of GSH levels. (**C**) Naive CD4^+^T cells from WT and *Gclm* KO (left), or WT (*CD4-Cre-, Gclc^fl/fl^*) and *Gclc* KO (*CD4-Cre+, Gclc^fl/fl^,* (middle), or WT and *Gsr* KO (right) were activated by plate-bound anti-CD3 plus anti-CD28 for 24 hr, followed by the measurement of ROS levels. Data in [Figure 1B--C](#fig1){ref-type="fig"} are representative of two independent experiments. Data represent the mean ± S.D.\
10.7554/eLife.36158.005Figure 1---source data 1.Source data for B and C.](elife-36158-fig1){#fig1}

To determine the extent to which de novo synthesis contributes to GSH production and redox homeostasis in T cells, we obtained mouse models with genetic deficiencies in GCL. GCLC possesses all the enzymatic activity, while GCLM functions to optimize the catalytic efficiency of the holoenzyme ([@bib10]). *Gclm* knockout (*Gclm* KO) mice carry the germ-line deletion of *Gclm*, whereas T cell-specific *Gclc* knockout (T cell*-Gclc* KO) mice, generated by crossing *Gclc-floxed* mice with CD4-Cre mice, carry the *Gclc* deletion exclusively in T cells ([@bib11]; [@bib114]). Absent expression of GCLM or GCLC in T cells derived from corresponding animals was confirmed by western blot ([Figure 1---figure supplement 1D](#fig1s1){ref-type="fig"}). Next, we examined the intracellular levels of GSH and ROS of T cells that were stimulated with anti-CD3 plus anti-CD28. Deficiency in GCLC (the catalytic subunit) and, to a lesser extent, deficiency in GCLM (modifier subunit) resulted in reduced intracellular content of GSH ([Figure 1B](#fig1){ref-type="fig"}). Consistent with this, we observed increased ROS in *Gclc*- and to a lesser extent in *Gclm*-deficient T cells as compared to WT T cells. ([Figure 1C](#fig1){ref-type="fig"}).

We then sought to determine the extent to which recycling of GSSG contributes to GSH production and redox homeostasis in T cells. For this, we obtained mice carrying germ-line deletion of *Gsr (Gsr^-/-^),* the deletion of which was demonstrated by qPCR ([Figure 1---figure supplement 1D](#fig1s1){ref-type="fig"}) ([@bib88]; [@bib85]; [@bib113]). However, WT and *Gsr*-deficient T cells displayed comparable GSH and ROS levels ([Figure 1B and C](#fig1){ref-type="fig"}). These results suggested that de novo synthesis of GSH by the metabolic pathway plays an indispensable role in producing GSH and maintaining redox homeostasis during T cell activation.

GCLC deficiency but not GCLM or GSR deficiency suppresses T cell activation and proliferation {#s2-2}
---------------------------------------------------------------------------------------------

*Gclm* KO, T cell*-Gclc* KO and *Gsr* KO mice contained comparable numbers and distribution of thymocytes and peripheral CD4^+^ and CD8^+^ T cells relative to control mice ([Figure 2---figure supplement 1A,B,C and D](#fig2s1){ref-type="fig"}), indicating a largely undisturbed T cell development and distribution after double positive stage in the absence of GSH recycling pathway or the de novo synthesis pathway. A recent study has showed that Gclc deficiency suppressed T cell activation and proliferation, demonstrating a critical role of GCLC in regulating T cell activation ([@bib58]; [@bib46]). This is consistent with the severe GSH depletion and ROS induction in *Gclc*-deficient active T cells ([Figure 1B and C](#fig1){ref-type="fig"}). Our results further suggested that GSR is dispensable and GCLM only play a minor role in modulating GSH production and ROS homeostasis in active T cells ([Figure 1B and C](#fig1){ref-type="fig"}). Next, we sought to differentiate the impact of GSH recycling pathway and de novo synthesis pathway on T cell activation and proliferation. While both Gclc and Gclm deficiency caused a reduction of GSH and induction of ROS, albeit to different degrees ([Figure 1B and C](#fig1){ref-type="fig"}), Gclc but not Gclm deficiency resulted in an impairment of cell viability, appearance of the activation marker CD25, and activation-induced cell proliferation ([Figure 2A, B, D, E and G](#fig2){ref-type="fig"}). This activation and proliferation defect is consistent with a recent study showing that GCLC is required for T cell activation ([@bib58]). Previous studies have shown that GSH depletion caused inactivation of glutathione peroxidase 4 (GPX4), and consequentially led to iron-dependent accumulation of lipid peroxidation and a form of cell necrosis referred as ferroptosis ([@bib99]). Our data suggested that a moderate reduced cell viability in *Gclc*-deficient T cells is likely due to ferroptosis in the context of GSH depletion ([Figure 2G](#fig2){ref-type="fig"}). Our results suggested that a severe depletion of GSH and induction of ROS caused by Gclc deficiency significantly impaired T cell activation and proliferation, however, active T cell could tolerate and cope with a moderate depletion of GSH and induction of ROS caused by Gclm deficiency.

![Severe depletion of GSH by blocking de novo synthesis suppresses T cell activation and proliferation.\
(**A--C**) Naive CD4 +T cells from WT and *Gclm* KO (**A**), or WT (*CD4-Cre-, Gclc^fl/fl^*) and *Gclc* KO (*CD4-Cre+, Gclc^fl/fl^*) (**B**), or WT and *Gsr* KO (**C**) mice were activated by plate-bound anti-CD3 plus anti-CD28 for 24 hr, followed by cell surface expression of CD25 (upper panel) and CD69 (lower panel). (**D--F**) Cell proliferation of active CD4 +T cells (72 hr) with indicated genotypes was determined by CFSE dilution. (**G**) Naive CD4 +T cells isolated from mice with indicated genotypes were activated by plate-bound anti-CD3 and anti-CD28 for 24 hr. Cell viability was determined by FACS. [Figure 2A--G](#fig2){ref-type="fig"} are representative of three independent experiments.](elife-36158-fig2){#fig2}

Consistent with its dispensable role in GSH production in active T cells ([Figure 1B and C](#fig1){ref-type="fig"}), Gsr deficiency did not lead to any impairment of T cell viability, activation marker CD25 and proliferation ([Figures 2C, F and G](#fig2){ref-type="fig"}). Notably, none of the above genetic deficiencies compromised the early activation marker CD69 ([Figure 2A--C](#fig2){ref-type="fig"}). Our results suggest that GSH recycling pathway is dispensable in regulating T cell activation and proliferation. However, the recycling of GSSG to GSH, which is not a parallel pathway for GSH production, plays a critical role in maintaining redox homeostasis when the ratio of GSSG:GSH reaches certain threshold. While our data suggest that Gsr mediated recycling of GSSG is not required for T cell activation and proliferation, we do not have evidence showing that GSSG is significantly accumulated during T cell activation and proliferation. Therefore, a dispensable role of Gsr in maintaining redox homeostasis during T cell activation and proliferation may represent a context-dependent interpretation.

Ablation of de novo synthesis but not recycling of GSSG reciprocally alters T~H~17 and iT~reg~ cell differentiation {#s2-3}
-------------------------------------------------------------------------------------------------------------------

Following the initial growth stage of cell activation, proliferating CD4^+^ T cells can differentiate into various functional subsets including inflammatory T~H~17 and Foxp3-expressing regulatory T cells (T~reg~ cells), which are two closely related subsets with distinct functions. Having found a role for de novo synthesis of GSH in modulating GSH and ROS homeostasis during T cell activation, we next assessed the functional requirement for the de novo synthesis pathway of GSH in T cell differentiation. Naive T cells were differentiated under T~H~17 or iT~reg~ conditions. As compared to control WT cells, *Gclm* KO cells exhibited reduced IL-17^+^ and increased Foxp3^+^ cells ([Figure 3A and D](#fig3){ref-type="fig"}). Given that a similar degree of proliferation was observed between WT and *Gclm* KO CD4^+^ T cells ([Figure 3A and D](#fig3){ref-type="fig"}), deregulation of cell differentiation in *Gclm* KO was largely independent of cell expansion. To bypass the effect of Gclc deficiency on T cell activation and proliferation ([Figure 2B and E](#fig2){ref-type="fig"}), we generated a mouse model carrying a conditional *Gclc* allele (*Gclc*^*flox/flox*^) and a tamoxifen-induced Cre recombinase (CreERT2) transgene ([@bib90]; [@bib19]), which allowed us to delete *Gclc* flox alleles in an acute manner. For this, we polarized T cells in the absence (WT) or in the presence (KO) of 4-Hydroxytamoxifen (4OHT) ([Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}). As compared with WT cells, acute deletion of Gclc bypassed its required for cell proliferation, as revealed by a comparable CFSE dilution ([Figure 3B and E](#fig3){ref-type="fig"}), but nevertheless resulted in a reduction in the generation of IL-17^+^ T cells and an induction in the generation of Foxp3^+^ cells. Using this genetic model, we have therefore differentiated the role of GCLC in early T cell activation from its role in driving T~H~17 cell differentiation. In contrast to the effects of ablation of *Gclm* and *Gclc*, *Gsr* KO and WT CD4^+^ T cells displayed a similar degree of T~H~17 and iT~reg~ differentiation, indicating a dispensable role for recycling GSSG in regulating T cell differentiation ([Figure 3C and F](#fig3){ref-type="fig"}). Next, we tested whether inhibiting ROS generation in T cells that have defects on the de novo synthesis of GSH would restore T~H~17 differentiation. The addition of N-acetyl-L-cysteine (NAC), a reagent often used to scavenge ROS, restored T~H~17 cell differentiation in *Gclc^-/-^* T cells ([Figure 3---figure supplement 1B](#fig3s1){ref-type="fig"}). While NAC is frequently considered a source of cysteine for synthesis of GSH, while other studies have shown that NAC displayed reducing properties through its thiol-disulfide exchange activity and could directly scavenge free radicals ([@bib4]; [@bib1]; [@bib115]; [@bib16]). Consistent with these, our result suggests that NAC scavenges ROS independently of GSH synthesis ([Figure 3---figure supplement 1C and D](#fig3s1){ref-type="fig"}) and therefore restores T~H~17 cell differentiation in *Gclc^-/-^* T cells. To further evaluate the role of the GSH de novo synthesis pathway in T~H~17-driven EAE in vivo, we immunized mice with the myelin oligodendrocyte glycoprotein (MOG)~35-55~ antigen. Genetic ablation of GCLM or GCLC conferred a protection against disease progression ([Figure 3G and H](#fig3){ref-type="fig"}). Furthermore, histological assessment revealed a similar degree of ablation of T cell infiltration in *Gclm* KO and T cell*-Gclc* KO animals compared to WT animals ([Figure 3---figure supplement 1E](#fig3s1){ref-type="fig"}). However, a different degree of ablation of macrophage infiltration in *Gclm* KO and T cell*-Gclc* KO animals compared to WT animals was observed and likely reflected a different level of inflammation in these experimental animals ([Figure 3---figure supplement 1E](#fig3s1){ref-type="fig"}). In contrast to T cell*-Gclc* KO animals, GCLM is also deleted in macrophages in *Gclm* KO animal (a germline KO model). Therefore, we could not exclude the possibility that Gclm deficiency in macrophages might affect macrophage infiltration in our result. Collectively, our studies suggested that de novo synthesis of GSH is required for T~H~17 development in vitro and T~H~17-driven CNS inflammation in vivo.

![Ablation of de novo synthesis but not recycling of GSSG reciprocally alters T~H~17 and iTreg cell differentiation.\
(**A--F**) Naive CD4+ T cells from WT and *Gclm* KO, or WT (*Cre-,) and CreER*+ (*Gclc*-KO- in the presence of 100 nM of 4-hydroxytamoxifen (4OHT)), or WT and *Gsr* KO mice were stained with 4 µm CFSE and differentiated under T~H~17 or iTreg -inducing conditions for 5 days, followed by intracellular staining of IL-17 and Foxp3. (**G--H**) mice with indicated genotypes were immunized with MOG to induce EAE and pathological progressions were scored daily. Data in [Figure 4A--H](#fig4){ref-type="fig"} are representative of two-three independent experiments.\
10.7554/eLife.36158.012Figure 3---source data 1.Source data for G and H.](elife-36158-fig3){#fig3}

T~H~17 and iT~reg~ cells display different degrees of oxidative stress {#s2-4}
----------------------------------------------------------------------

Accumulating evidence has shown that each subset of T cells engages unique metabolic pathways to fulfill its metabolic demands ([@bib95]; [@bib63]; [@bib30]). We envisioned that the differential engagement of metabolic pathways would differentially impact GSH biosynthesis and cellular oxidative stress in T~H~17 and iT~reg~ cells. For this, we activated naive CD4^+^ T cells under T~H~17 or iT~reg~ polarizing conditions in vitro, and examined the intracellular levels of GSH and ROS at day 3 and day 5. T~H~17 cells displayed a higher level of intracellular GSH than iT~reg~ cells. In contrast, the level of ROS was lower in T~H~17 cells compared to iT~reg~ cells ([Figure 4A and B](#fig4){ref-type="fig"}). In addition, T~H~17 cells displayed a higher level of intracellular GSH and GSSG than iT~reg~ cells, as revealed by mass spectrometry ([Figure 4C](#fig4){ref-type="fig"}). A key cellular mechanism in defending against oxidative stress is through activation of nuclear factor erythroid 2-related factor 2 (NRF2), which controls the expression of genes involved in producing, regenerating, and utilizing GSH. NRF2 also controls other antioxidant pathways that regulate thioredoxin (*TXN*), NADPH generation and iron sequestration ([@bib40]; [@bib98]; [@bib56]; [@bib68]). Consistent with increased levels of GSH and decreased levels of ROS in T~H~17 cells, qPCR analysis revealed a time-dependent up-regulation of mRNAs encoding NRF2 and its target genes, including glucose-6-phosphate dehydrogenase (*G6PD*), *TXN*, thioredoxin reductase 1 (*Txnrd1*), CD44, heme oxygenase-1 (*Hmox1*), NAD(P)H quinone dehydrogenase 1 (*Nqo1*) and glutathione synthetase (*Gss*) ([Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}). These results suggested that T~H~17 cells preferentially maintain a low degree of oxidative stress by a tight regulation of GSH synthesis and ROS homeostasis.

![T~H~17 cells preferentially maintain higher level of GSH than iT~reg~ cells.\
(**A--B**) Naive CD4^+^ T cells from C57BL/6 mice were differentiated under iTreg or T~H~17--inducing conditions and cells were collected at indicated times, followed by measuring intracellular GSH (**A**) and ROS (**B**) by FACS. (**C**) Naive CD4^+^ T cells from C57BL/6 mice were differentiated under T~H~17 or iT~reg~--inducing conditions for 5 days. The intracellular levels of GSH and GSSG were determined by mass spectrometry. (**D**) Naive CD4^+^T cells from WT and *Gclm* KO (top) or WT (*CD4-Cre-, Gclc^fl/fl^*) and *Gclc* KO (*CD4-Cre+, Gclc^fl/fl^*, (bottom) were differentiated under T~H~17-inducing conditions for 5 days, followed by the measurement of GSH levels. Data in [Figure 4A--D](#fig4){ref-type="fig"} are representative of three independent experiments. Data represent the mean ± S.D.\
10.7554/eLife.36158.016Figure 4---source data 1.Source data for A, B, C and D.](elife-36158-fig4){#fig4}

De novo synthesis but not recycling of GSSG is required for producing GSH and suppressing ROS during T~H~17 cell differentiation {#s2-5}
--------------------------------------------------------------------------------------------------------------------------------

The observation that T~H~17 cells displayed increased GSH content and decreased levels of ROS than iT~reg~ cells supported the role for GSH in directing T~H~17 cell differentiation ([Figure 4A and B](#fig4){ref-type="fig"}). Next, we sought to determine how two GSH synthetic pathways are engaged and impact on GSH and ROS homeostasis during T~H~17 cell differentiation. For this, we purified naive T cells and differentiated them under T~H~17-polarizing conditions. Deficiency in Gclc and, to a lesser extent, deficiency in Gclm resulted in reduced intracellular content of GSH ([Figure 4D](#fig4){ref-type="fig"}). Consistent with this, we observed increased ROS in *Gclc*- and *Gclm*-deficient T cells as compared to WT T cells ([Figure 4---figure supplement 1B and C](#fig4s1){ref-type="fig"}). By contrast, WT and *Gsr*-deficient T cells displayed comparable GSH sand ROS levels ([Figure 4---figure supplement 1D](#fig4s1){ref-type="fig"}). These results indicated that the preferential requirement for de novo synthesis of GSH during the initial T cell activation stage is extended to the later T cell differentiation stage. However, the recycling pathway is dispensable in producing GSH and maintaining redox homeostasis during T~H~17 differentiation.

Pharmacological augmentation of ROS reciprocally modulates T~H~17 and iT~reg~ cell differentiation {#s2-6}
--------------------------------------------------------------------------------------------------

We next asked whether shifting the redox balance towards an oxidative state would perturb T cell differentiation and represent a novel therapeutic strategy for T cell-driven autoimmunity. For this, we activated naive CD4^+^ T cells under T~H~17 or iT~reg~ polarizing conditions in the presence or absence of H~2~O~2~. Addition of 1 μM H~2~O~2~ did not impact cell proliferation but reciprocally reduced T~H~17 and enhanced iT~reg~ cell differentiation ([Figure 5A and B](#fig5){ref-type="fig"}), indicating that its effect on differentiation was largely independent of expansion.

![DMF suppresses T~H~17 differentiation by augmenting ROS generation.\
(**A**) Naive CD4^+^ T cells from C57BL/6 mice were differentiated under T~H~17 or iT~reg~-inducing conditions with or without H~2~O~2~ (1 µM) for 5 days, followed by intracellular staining of IL-17 and Foxp3. (**B**) Cell proliferation of active CD4^+^ T cells (72 hr) with or without H~2~O~2~ (1 µM) was determined as CFSE dilution. (**C--D**) Naive CD4^+^ T cells from C57BL/6 mice were differentiated under T~H~17-inducing conditions with indicated dose of DMF for 5 days, followed by intracellular staining of IL-17 (**C**) and ROS (**D**). (**E**) Naive CD4^+^ T cells from C57BL/6 mice were differentiated under T~H~17-inducing conditions with indicated treatment for 5 days, followed by intracellular staining of IL-17. Data in [Figure 5](#fig5){ref-type="fig"} are representative of two-three independent experiments. Data represent the mean ±S.D.\
10.7554/eLife.36158.019Figure 5---source data 1.Source data for D.](elife-36158-fig5){#fig5}

The observation of H~2~O~2~-dependent suppression of T~H~17 differentiation prompted us to explore pharmacologic approaches that could augment ROS production in T cells. Dimethyl fumarate (DMF), the key active ingredient of BG-12/TECFIDERA and FUMADERM, has been approved in many countries for treating autoimmune diseases including multiple sclerosis (MS) and psoriasis, both of which are associated with pathogenic T~H~17 cells ([@bib100]; [@bib69]; [@bib20]; [@bib14]). However, the cellular and molecular mechanisms underlying the therapeutic efficacy of DMF have not been fully elucidated ([@bib45]). Previous studies have implicated DMF in regulating the cellular activities of dendritic cells (DCs), endothelial cells, and neurons through various mechanisms ([@bib7]; [@bib92]; [@bib110]; [@bib12]; [@bib81]; [@bib52]; [@bib22]; [@bib32]). The electrophilic nature of DMF allows it to bind and deplete intracellular GSH ([@bib118]; [@bib101]). We therefore hypothesized that DMF may induce oxidative stress and affect T cell differentiation. To test this, we activated naive CD4^+^ T cells under T~H~17 polarizing conditions in the presence of a range of DMF doses based on previous reports that were designed to investigate the effect of DMF on other cell types ([@bib81]; [@bib52]; [@bib22]). DMF treatment displayed a dosage-dependent suppression of T~H~17 cell differentiation ([Figure 5C](#fig5){ref-type="fig"}). Although the addition of 75 μM DMF inhibited T cell proliferation, at the lower dose of DMF used in this study (20--50 μM), we observed minimal inhibitory effects of DMF on cell proliferation ([Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"}), indicating that DMF-mediated suppression on T~H~17 differentiation was largely independent of cell proliferation. Moreover, DMF treatments induced ROS production in T~H~17 cells ([Figure 5D](#fig5){ref-type="fig"}). Consistent with the idea that DMF suppresses T~H~17 cell differentiation through the induction of oxidative stress, the addition of N-acetyl-L-cysteine (NAC) restored T~H~17 cell differentiation in the presence of DMF ([Figure 5E](#fig5){ref-type="fig"}). Since H~2~O~2~ treatment reciprocally reduced T~H~17 and enhanced iT~reg~ cell differentiation ([Figure 5A and B](#fig5){ref-type="fig"}), we next assessed the effect of DMF on iT~reg~ cell differentiation. However, the doses of DMF (5 and 20 μM) that could suppress T~H~17 differentiation failed to affect iT~reg~ cell differentiation in vitro ([Figure 5---figure supplement 1B](#fig5s1){ref-type="fig"}). As such, our data suggested that DMF may partially exert its immunomodulatory action through the augmentation of oxidative stress and suppressing T~H~17 differentiation. Along with the possibility that DMF-derived fumarate interferes with TCA cycle intermediate metabolite pool, other mechanisms may also contribute to its immunomodulatory functions ([@bib7]; [@bib92]; [@bib110]; [@bib12]; [@bib81]; [@bib52]; [@bib22]; [@bib32]).

Glutamate that fuels GSH de novo synthesis is partially derived from glutamine during T~H~17 cell differentiation {#s2-7}
-----------------------------------------------------------------------------------------------------------------

Upon activation, a metabolic reprogramming is required for directing nutrients to meet the bioenergetic, biosynthetic, and redox demands, which prepares T cells for immune defense and regulation. We and others have shown that T cell metabolism changes from relying on FAO and some mitochondria-dependent glucose oxidation to engaging robust aerobic glycolysis and glutaminolysis ([@bib107]; [@bib28]; [@bib39]; [@bib31]; [@bib78]). Glutamine catabolism not only fuels mitochondrial ATP production through the TCA cycle but also provides metabolic precursors for multiple biosynthetic pathways, including synthesis of glutathione (GSH), an essential cellular antioxidant system to maintain redox homeostasis during T cell activation ([@bib3]; [@bib35]; [@bib33]; [@bib58]). The de novo synthesis of GSH requires glycine, cysteine and glutamate as metabolic precursors. We envisioned that glutamine-derived glutamate partially fulfils the requirement of de novo synthesis of GSH in T~H~17 cells ([Figure 6A](#fig6){ref-type="fig"}). To test this hypothesis, we followed U-^13^C,^15^N labeled glutamine incorporation into glutamate and GSH. The ^13^C~5~ isotopologues (generated via a direct Glutamine to Glutmate conversion) represented a significant fraction of the total glutamate and GSH pool in both T~H~17 and iT~reg~ cells, however, the absolute quantity of ^13^C~5~-glutamate and ^13^C~5~-GSH is higher in T~H~17 cells than in iT~reg~ cells ([Figure 6B](#fig6){ref-type="fig"}). These results suggested that T~H~17 cells could uptake more glutamine and/or produce more glutamate for GSH synthesis than iT~reg~ cells. In accord with this data, glutamine starvation reduced GSH content in a time-dependent manner in T~H~17 cells ([Figure 6---figure supplement 1A](#fig6s1){ref-type="fig"}). In addition to support GSH biosynthesis, glutamine-derived glutamate can also feed into the TCA cycle. We therefore utilized radiochemical-based approaches to assess activities of glutamine oxidation through the TCA cycle in T~H~17 and iT~reg~ cells. T~H~17 cells displayed higher glutamine oxidation activity, indicated by ^14^CO~2~ release from \[U-^14^C\]-glutamine, than did iT~reg~ cells ([Figure 6C](#fig6){ref-type="fig"}). However, mitochondria-dependent pyruvate oxidation through the TCA cycle, indicated by ^14^CO~2~ release from \[2-^14^C\]-pyruvate, was comparable between the two functional subsets ([Figure 6C](#fig6){ref-type="fig"}). These data further suggested that the overall uptake and consumption of glutamine, including oxidation of glutamate through the TCA cycle and utilization of glutamate for GSH biosynthesis is enhanced in T~H~17 comparing to iT~reg~ cells. Also, qPCR analyses revealed marked upregulation of genes encoding various molecules involved in glutamine catabolism and GSH metabolism in T~H~17 compared to iT~reg~ cells ([Figure 6---figure supplement 1B and C](#fig6s1){ref-type="fig"}). Consistent with this, deprivation of glutamine significantly suppressed T~H~17 but moderately enhanced iT~reg~ cell differentiation ([Figure 6D](#fig6){ref-type="fig"}), while both T~H~17 and iT~reg~ differentiation required glucose ([Figure 6E](#fig6){ref-type="fig"}). Next, we asked if pharmacological inhibition of the rate-limiting glutaminolyic enzyme glutaminase (Gls) could impact T cell differentiation. Two Gls1 specific inhibitors, bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl) ethyl sulfide (BPTES) and CB-839 ([@bib106]; [@bib50]), slightly enhanced IL-17 expression ([Figure 6---figure supplement 1D](#fig6s1){ref-type="fig"}). However, 6-diazo-5-oxo-l-norleucine (DON), an analog of glutamine with broad inhibitory effects glutamine utilizing enzymes ([@bib83]; [@bib94]), skewed away T cells from T~H~17 toward iT~reg~ differentiation ([Figure 6---figure supplement 1D](#fig6s1){ref-type="fig"}). In addition, DON but not BPTES and CB-839 significantly enhanced ROS production under T~H~17-polarizing condition ([Figure 6---figure supplement 1E](#fig6s1){ref-type="fig"}). These results suggested that other glutamine utilizing enzymes including glutamine-dependent amidotransferase and Gls2, the latter of which has been shown to be induced upon T cell activation ([@bib107]; [@bib116]; [@bib60]).Glutamine catabolism is not only coupled to the de novo synthesis of GSH, but also generates the anaplerotic substrate, α-ketoglutarate (α-KG), and substrates for nucleotide biosynthesis([@bib3]). A previous study demonstrated that glutamine deprivation enhances iTreg differentiation and addition of α-KG could compromise such effect ([@bib47]). In line with this report, addition of either hypoxanthine and thymidine (HT) or α-KG was able to partially rescue T~H~17 differentiation in glutamine-free condition without impacting ROS level ([Figure 6F and G](#fig6){ref-type="fig"}). While NAC treatment is sufficient to suppress ROS production, it was incapable of rescuing T~H~17 differentiation ([Figure 6---figure supplement 1G](#fig6s1){ref-type="fig"}). However, the combination of HT and NAC led to more differentiated T~H~17 cells and lower level of ROS comparing to HT treatment alone in the absence of glutamine ([Figure 6---figure supplement 1F](#fig6s1){ref-type="fig"}). Taken together, our studies suggest that glutamine catabolism directs the lineage choices between T~H~17 and iT~reg~ cells through supporting T cell proliferation by providing biosynthetic precursors. In addition, glutamine-derived glutamate provides a key substrate for the de novo synthesis of GSH, modulates ROS signaling, and may also impact T cell differentiation ([Figure 6---figure supplement 2](#fig6s2){ref-type="fig"}).

![Glutamate that fuels GSH de novo synthesis is partially derived from glutamine in T cells.\
(**A**) Diagram of metabolic steps linked to the GSH production, with metabolic pathways highlighted in red. (**B**) Naive CD4^+^ T cells from C57BL/6 mice were differentiated under T~H~17 and iT~reg~--inducing conditions for 5 days, followed by culturing in media containing ^13^C~5~^15^N~2~-glutamine. The intracellular levels of Glutamate and GSH including ^13^C-, ^13^C,^15^N-, and ^12^C-unlabeled forms were determined by IC-UHRFTMS. (**C**) Naive CD4^+^ T cells from C57BL/6 mice were differentiated under T~H~17 or iT~reg~ cell--inducing conditions for 5 days, were used for measuring the generation of ^14^CO2 from \[U-^14^C\]-glutamine (glutaminolysis), from \[2-^14^C\]-pyrvuate (TCA). (**D--E**) Naive CD4^+^ T cells from C57BL/6 mice were differentiated in completed, glutamine-free (Q free) or glucose-free (G free) medium under T~H~17 or iT~reg~ cell-inducing conditions for 5 days, followed by intracellular staining of IL-17 and Foxp3. (**F**) Naive CD4^+^ T cells from C57BL/6 mice were activated in complete medium for 24 hr and cells were washed with PBS and switch to conditional medium in presence or absence of glutamine, 3 mM αKG or 100 μM hypoxanthine and 16 μM thymidine (HT) for 5 days followed by intracellular staining of IL-17 and (**G**) and ROS. Data represent the mean ±S.D.\
10.7554/eLife.36158.024Figure 6---source data 1.Source data for B, C and G.](elife-36158-fig6){#fig6}

Discussion {#s3}
==========

A robust T cell-mediated adaptive immune response results from the clonal expansion of antigen-specific T cells and subsequent differentiation into diverse functional subsets to fine-tune responses against challenge. Both the cellular proliferation during expansion and the cytokine production associated with differentiation exert high bioenergetic and biosynthetic demand on T cells. Accordingly, rapidly evolving pathogens often impose selective pressures on the regulation of central metabolic pathways that fuel cell proliferation and differentiation, allowing T cells to maintain homeostasis while remaining ready to mount rapid responses under diverse metabolic and immune conditions. The inability to accommodate the metabolic and bioenergetic demands of T cell proliferation and differentiation can impair the proper development and function of T cells. Beyond this, the availability of specific metabolites, and the pathways that process them, interconnect with signaling events in the cell to orchestrate metabolic checkpoints which influence T cell activation, differentiation, and immune function ([@bib108]; [@bib6]; [@bib31]; [@bib80]; [@bib13]; [@bib84]; [@bib64]; [@bib36]). Here, we found that glucose plays an indispensable role in driving T~H~17 and iT~reg~ cell differentiation, while glutamine is only required for T~H~17 cell differentiation. Glutamine catabolism is coupled with de novo GSH synthesis and is preferentially elevated during T~H~17 but not iT~reg~ cell differentiation, suggesting that different T cell lineages 'wire' metabolism differently to support their development and function. Previous studies have suggested that engagement of the transcription factor hypoxia-inducible factor 1α (HIF1α) coordinates glycolysis and T cell signaling cascades to regulate the differentiation of T~H~17 and iTreg cells ([@bib95]; [@bib18]). While the high rate of glutamine catabolism ensures the capacity to supply glutamate, glycolysis provides ATP and biosynthetic precursors for glycine, fulfilling the needs of de novo synthesis of GSH during T cell differentiation. Our results using genetic modulation of metabolic enzymes suggest that de novo synthesis of GSH but not recycling from GSSG is required for fine-tuning ROS and directing the differentiation of T~H~17 and T~reg~ cells. We further found that dimethyl fumarate, a FDA approved drug (BG-12/Tecfidera) for multiple sclerosis, suppresses T~H~17 differentiation by augmenting intracellular ROS. While previous studies clearly demonstrate that activation-induced metabolic reprogramming is required for driving T cell growth and proliferation, our studies shed light on the complex utilization of the glutamine catabolic pathway and implicate ROS as essential metabolic signals that dictate T cell lineage engagement.

Prokaryotic and eukaryotic cells have evolved to maintain reducing intracellular conditions by generating reducing equivalents, NADPH and GSH, enabling cells to fine-tune the ROS levels that are required for fulfilling vital cellular functions. Accordingly, oxidative stress occurs if the balance between ROS production and antioxidant capacity is disturbed, thereby leading to the accumulation of oxidized biomolecules. T cell receptor (TCR) engagement induces a rapid generation of mitochondrial ROS from OXPHOS and cytoplasmic ROS from NADPH oxidases (NOXs), a family of plasma membrane associated oxidases ([@bib93]; [@bib42]; [@bib38]). T cells with reduced production of mitochondrial ROS display impaired production of interleukin 2 (IL-2) and antigen-specific proliferation, indicating an essential signaling role for mitochondrial ROS in driving optimal TCR signaling ([@bib93]; [@bib42]). Beyond that, NOX-dependent ROS also plays a role in modulating TCR signaling and T cell differentiation. T cells with low levels of ROS due to NOX deficiency are skewed toward a T~H~17 phenotype ([@bib38]; [@bib86]; [@bib75]; [@bib104]). Our studies suggest that de novo synthesis of GSH is essential for fine-tuning ROS levels in T cells and also indicate the differential requirements for the level of ROS in driving T cell lineage engagement toward T~H~17 or iT~reg~ cells. Understanding the metabolic process of GSH synthesis and ROS generation during T cell differentiation may also impact the development of safer and more effective therapies for autoimmune and inflammation diseases. Dimethyl fumarate (DMF) is a cellular permeable analog of fumarate and the key active ingredient of BG-12/TECFIDERA and FUMADERM, a first-line oral treatment for relapsing multiple sclerosis ([@bib14]; [@bib2]). However, the cellular and molecular mechanisms of DMF therapy remain largely elusive. DMF has been suggested to impact a plethora of cellular and molecular targets, including Nrf2 and GPCRs in T cells, dendritic cells (DCs), endothelial cells, and neurons ([@bib7]; [@bib92]; [@bib110]; [@bib12]; [@bib81]; [@bib52]; [@bib22]; [@bib32]). Consistent with the studies showing that DMF can neutralize GSH in vitro ([@bib118]; [@bib101]), our data indicate that the ability of DMF to augment ROS and suppress T~H~17 cell differentiation contributes to its therapeutic effect.

We found that DMF treatment induced a compensatory NRF2-mediated anti-oxidative response and NRF2 deficiency exacerbated the ROS-producing effects of DMF in T~H~17 cells. Also, NRF2 and its target genes were highly upregulated in T~H~17 cells, suggesting that T~H~17 cells preferentially maintain a low degree of oxidative stress partially by engaging the NRF2 signaling pathway. In addition to GSH production and consumption, NRF2 controls thioredoxin (TXN) production and consumption through transcriptional regulation of its target genes including thioredoxin reductase 1 (TXNRD1). Both GSH and TXN are important anti-oxidation systems and appear functionally redundant in most organisms ([@bib17]; [@bib72]; [@bib51]; [@bib55]). However, recent studies implicate the presence of a dynamic cross-talk between these two systems. Glutaredoxin (GRX)-GSH can reduce oxidized TXN in the absence of thioredoxin reductase. Conversely, TXN-TXNRD can also function as an alternative system to reduce GSSG to GSH ([@bib21]; [@bib103]; [@bib41]; [@bib34]). Collectively, these data indicate that the TXN and GSH systems can backup for each other under certain conditions. Consistent with the overlapping function of the GSH and TXN system, the inhibition of TXNRD rendered cancer cells susceptible to the depletion of GSH ([@bib59]; [@bib53]; [@bib109]). Although our data suggest that the de novo synthesis of GSH is sufficient to maintain ROS homeostasis in the absence of Gsr dependent GSSG-GSH recycling, it is still conceivable that thioredoxin reductase may partially compensate for the loss of Gsr by backing up the recycle of GSSG to GSH in T cells. It has been shown that TXN can be secreted by CD4^+^ T cells and may modulate the expression of T cell surface receptor and proliferation ([@bib89]; [@bib105]; [@bib61]; [@bib102]). As such, we envision that the combination of DMF and pharmacological approaches that target TXN system may represent a more effective strategy than DMF alone for treating T cell-mediated inflammation and autoimmune disease.

Materials and methods {#s4}
=====================

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\         Designation                Source or reference                                                 Identifiers                                                    Additional\
  (species) or\                                                                                                                                                                       information
  resource                                                                                                                                                                            
  --------------------- -------------------------- ------------------------------------------------------------------- -------------------------------------------------------------- -------------
  Strain, strain\       C57BL/6 (B6) mice                                                                              Taconic                                                        
  background\                                                                                                                                                                         
  (Mus musculus)                                                                                                                                                                      

  Strain, strain\       C3H/HeN                                                                                        Envigo                                                         
  background\                                                                                                                                                                         
  (Mus musculus)                                                                                                                                                                      

  Genetic\              *CD4-Cre*\                 PMID:23226398                                                                                                                      
  reagent\              *Gclc^flox/flox^*                                                                                                                                             
  (Mus musculus)                                                                                                                                                                      

  Genetic\              *Gclm-*KO                  PMID:12384496                                                                                                                      
  reagent\                                                                                                                                                                            
  (Mus musculus)                                                                                                                                                                      

  Genetic\              *ROSA26CreERT2*            RRID:\                                                              The Jackson\                                                   
  reagent\                                         [IMSR_JAX:008463](https://scicrunch.org/resolver/IMSR_JAX:008463)   Laboratory                                                     
  (Mus musculus)                                                                                                                                                                      

  Genetic\              *GSR-*KO                   PMID: 10218442                                                                                                                     
  reagent\                                                                                                                                                                            
  (Mus musculus)                                                                                                                                                                      

  Antibody              Mouse anti-\               Cat. \#:BE0001-1,\                                                  BioXcell                                                       
                        CD3 mAb                    RRID:[AB_1107634](https://scicrunch.org/resolver/AB_1107634)                                                                       

  Antibody              Mouse anti-\               Cat. \#BE0015-1\                                                    BioXcell                                                       
                        CD28 mAb                   RRID:[AB_1107624](https://scicrunch.org/resolver/AB_1107624)                                                                       

  Antibody              Mouse anti\                Cat.\#BE0043\                                                       BioXcell                                                       
                        -IL2 mAb                   RRID::AB_1107702                                                                                                                   

  Antibody              Mouse anti-\               Cat. \#BE0045\                                                      BioXcell                                                       
                        IL4 mAb                    RRID:[AB_1107707](https://scicrunch.org/resolver/AB_1107707)                                                                       

  Antibody              Mouse anti-\               Cat. \#BE0055\                                                      BioXcell                                                       
                        IFNγ mAb                   RRID:[AB_1107694](https://scicrunch.org/resolver/AB_1107694)                                                                       

  Antibody              Anti mouse\                Cat. \#11--0042\                                                    eBioscience                                                    (1:200)
                        CD4-FITC                   RRID:[AB_464897](https://scicrunch.org/resolver/AB_464897)                                                                         

  Antibody              Anti mouse\                Cat. \#17-0041-81\                                                  eBioscience                                                    (1:200)
                        CD4-APC                    RRID:[AB_469319](https://scicrunch.org/resolver/AB_469319)                                                                         

  Antibody              Anti mouse\                Cat. \#100714\                                                      Biolegend                                                      (1:200)
                        CD8-APC-Cy7                RRID:[AB_312753](https://scicrunch.org/resolver/AB_312753)                                                                         

  Antibody              Anti mouse\                Cat. \#\                                                            eBioscience                                                    (1:200)
                        Foxp3-APC                  RRID:[AB_469456](https://scicrunch.org/resolver/AB_469456)                                                                         

  Antibody              Anti mouse\                Cat. \#25-7177-82\                                                  eBioscience                                                    (1:200)
                        IL-17A-PECy7               RRID:[AB_10732356](https://scicrunch.org/resolver/AB_10732356)                                                                     

  Antibody              Anti GCLC antibody\        Cat. \#ab190685\                                                    Abcam                                                          WB (1:1000)
                        (rabbit monoclonal)        RRID:[AB_10975474](https://scicrunch.org/resolver/AB_10975474)                                                                     

  Antibody              Anti GCLM antibody\        Cat. \#ab124827\                                                    Abcam                                                          WB (1:1000)
                        (rabbit monoclonal)        RRID:[AB_10975474](https://scicrunch.org/resolver/AB_10975474)                                                                     

  Antibody              anti-mouse\                Cat. \#101904\                                                      Biolegend                                                      (1:200)
                        CD25 -PE                   RRID:[AB_312847](https://scicrunch.org/resolver/AB_312847)                                                                         

  Antibody              anti-mouse\                Cat. \#552879\                                                      BD Bioscience                                                  (1:200)
                        CD69-PECy7                 RRID:[AB_394508](https://scicrunch.org/resolver/AB_394508)                                                                         

  Antibody              Anti mouse\                Cat. \#sc-101442\                                                   Santa Cruz                                                     IHC (1:50)
                        monoclonal CD3             RRID:[AB_1120355](https://scicrunch.org/resolver/AB_1120355)                                                                       

  Antibody              Anti mouse\                Cat. \#sc-32790,\                                                   Santa Cruz                                                     IHC (1:50)
                        monoclonal\                RRID:[AB_627657](https://scicrunch.org/resolver/AB_627657)                                                                         
                        galectin-3                                                                                                                                                    

  Peptide,\             MOG35-55 peptide           synthesized\                                                        St. Jude\                                                      
  recombinant protein                              and HPLC-purified                                                   Hartwell Center\                                               
                                                                                                                       for Biotechnology                                              

  Peptide,\             Recombinant\               216--16                                                             Peprotech                                                      
  recombinant protein   mouse IL-6                                                                                                                                                    

  Peptide,\             Recombinant\               100--21 c                                                           Peprotech                                                      
  recombinant protein   human TGFb                                                                                                                                                    

  Peptide,\             Recombinant\               200--02                                                             Peprotech                                                      
  recombinant protein   human or mouse IL-2                                                                                                                                           

  Commercial\           Foxp3/Transcription\       00-5523-00                                                          e-Bioscience                                                   
  assay or kit          Factor Staining\                                                                                                                                              
                        Buffer Set                                                                                                                                                    

  Commercial\           Naive CD4 + T cell\        5160725186                                                          Miltenyi Biotec                                                
  assay or kit          isolation kit,mouse                                                                                                                                           

  Commercial\           CD45R(B220)\               5150309030                                                          Miltenyi Biotec                                                
  assay or kit          microbeads, mouse                                                                                                                                             

  Commercial\           ABC kit                    PK-7200                                                             Vector\                                                        
  assay or kit                                                                                                         laboratories                                                   

  Commercial\           MojoSort Mouse\            480031                                                              Biolegend                                                      
  assay or kit          naive CD4 T Cell\                                                                                                                                             
                        Isolation Kit                                                                                                                                                 

  Chemical\             Diethly Fumerate           Sigma Aldrich                                                       D95654                                                         
  compound, drug                                                                                                                                                                      

  Chemical\             N-Acetyl-L-cysteine        Sigma-Aldrich                                                       A7250                                                          
  compound, drug                                                                                                                                                                      

  Chemical\             Tamofixen                  Sigma-Aldrich                                                       T5648                                                          
  compound, drug                                                                                                                                                                      

  Chemical\             4-hydroxytamoxifen         Sigma                                                               H7904                                                          
  compound, drug                                                                                                                                                                      

  Chemical\             Dimethy a-keto\            Sigma-Aldrich                                                       34963--1                                                       
  compound, drug        glutarate/aKG                                                                                                                                                 

  Chemical\             Hypoxathine                Sigma-Aldrich                                                       H9377                                                          
  compound, drug                                                                                                                                                                      

  Chemical\             Thymidine                  Sigma                                                               T9250                                                          
  compound, drug                                                                                                                                                                      

  Chemical\             H2O2                       Sigma-Aldrich                                                       7722-84-1                                                      
  compound, drug                                                                                                                                                                      

  Chemical\             carboxyfluorescein\        Invitrogen                                                          C1157                                                          
  compound, drug        diacetate\                                                                                                                                                    
                        succinimidyl\                                                                                                                                                 
                        ester(CFSE)                                                                                                                                                   

  Chemical\             DM-H2DCFDA                 Invitrogen                                                          C6827                                                          
  compound, drug                                                                                                                                                                      

  Chemical\             DAB                        Vector\                                                             SK-4100                                                        
  compound, drug                                   Laboratories                                                                                                                       

  Chemical\             Monobromobimane            Invitrogen                                                          M1378                                                          
  compound, drug                                                                                                                                                                      

  Chemical\             7-amino-\                  Biolegend                                                           420404                                                         
  compound, drug        actinomycin D(7AAD)                                                                                                                                           

  Chemical\             Pertussis toxin            181                                                                 List Biological\                                               
  compound, drug                                                                                                       Laboratories                                                   

  Chemical\             Mycobacterium\             231141                                                              Difco                                                          
  compound, drug        tuberculosum                                                                                                                                                  

  Chemical\             Incomplete\                263910                                                              Difco                                                          
  compound, drug        Freund's Adjuvant                                                                                                                                             

  Chemical\             \[U-14C\]-glutamine        MC 1124                                                             Moravek                                                        
  compound, drug                                                                                                                                                                      

  Chemical\             \[2--14C\]-pyruvate        ARC 0222                                                            American\                                                      
  compound, drug                                                                                                       Radiolabeled\                                                  
                                                                                                                       Chemicals                                                      

  Chemical\             Cell Stimulation\          00-4975-93                                                          eBioscience                                                    
  compound, drug        Cocktail (plus\                                                                                                                                               
                        protein transport\                                                                                                                                            
                        inhibitors) (500X)                                                                                                                                            

  Chemical\             Iscove\'s Modified\        ME17058P1                                                           Thermo\                                                        
  compound, drug        Dulbecco\'s Media\                                                                             Fisher Scientific                                              
                        - Glucose free\                                                                                                                                               
                        conditional medium                                                                                                                                            

  Chemical\             Iscove\'s Modified\        12--726 f                                                           Lonza                                                          
  compound, drug        Dulbecco\'s Media\                                                                                                                                            
                        - without L-glutamine                                                                                                                                         

  Chemical\             RPMI 1640\                 11-879-020                                                          Gibco                                                          
  compound, drug        Medium, No Glucose                                                                                                                                            

  Chemical\             Hyclone RPMI\              sh30096.10                                                          Thermo\                                                        
  compound, drug        1640 Medium,\                                                                                  Fisher Scientific                                              
                        no glutamine                                                                                                                                                  

  Chemical\             U-13C6-glutamine           CNLM-1275--0.1                                                      Cambridge\                                                     
  compound, drug                                                                                                       Isotope Lab                                                    

  Chemical\             6-Diazo-5-oxo-L\           D2141-5MG                                                           Sigma-aldrich                                                  
  compound, drug        -norleucine                                                                                                                                                   

  Chemical\             Bis-2-\                    SML0601                                                             Sigma-aldrich                                                  
  compound, drug        (5-phenylacetamido\                                                                                                                                           
                        -1,3,4-thiadiazol-2-yl)\                                                                                                                                      
                        ethyl sulfide (BPTES)                                                                                                                                         

  Chemical\             CB-839                     22038                                                               Cayman                                                         
  compound, drug                                                                                                                                                                      

  Software,\            Graphpad Prism                                                                                 RRID:[SCR_002798](https://scicrunch.org/resolver/SCR_002798)   
  algorithm                                                                                                                                                                           

  Software,\            FlowJo                                                                                         RRID:[SCR_008520](https://scicrunch.org/resolver/SCR_008520)   
  algorithm                                                                                                                                                                           
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Mice {#s4-1}
----

*Gsr-*KO mice are on C3H/HeN background and *ROSA26CreERT2, CD4-Cre, Gclm-*KO, and *Gclc^flox/flox^* are on the C57BL/6 background and were previously described ([@bib107]; [@bib11]; [@bib114]; [@bib88]; [@bib85]; [@bib113]) C57BL/6 mice were purchased from Envigo (formly Harlan). Mice at 8--12 weeks of age were used in the experiment and were kept in specific pathogen-free conditions within the Animal Resource Center at the Research Institute at Nationwide Children's Hospital or St. Jude Children\'s, Research Hospital. Animal protocols were approved by the Institutional Animal Care and Use Committee of the Research Institute at Nationwide Children's Hospital or St. Jude Children\'s Research Hospital.

Flow cytometry {#s4-2}
--------------

For analysis of surface markers, cells were stained in PBS containing 2% (wt/vol) BSA and the appropriate antibodies from eBioscience. Foxp3 staining was performed according to the manufacturer\'s instructions (eBioscience). For IL-17A intracellular cytokine staining, T cells were stimulated for 4-5 h with phorbol 12-myristate 13-acetate (PMA) and ionomycin in the presence of monensin before being stained according to the manufacturer\'s instructions (BD Bioscience). For ROS measurement, cells were cultured in fresh serum-free IMDM media containing 5 μM H~2~DCF-DA (BD Bioscience) for 30 min at 37°C before being washed and resuspended with serum-free IMDM media. The fluorescence intensity was measured by flow cytometry. For GSH measurement, cells were cultured in PBS (1%FBS) containing 50μM monobromobimane (Biochemika) for 10 min at 37°C before being washed and resuspended with PBS. The fluorescence at 450/50 nm (blue spectra) was measured by flow cytometry ([@bib15]). Flow cytometry data were acquired on Novocyte (ACEA Biosciences) or LSRII (Becton Dickinson) and were analyzed with FlowJo software (TreeStar).

Cell purification and culture {#s4-3}
-----------------------------

Total T cells or naive CD4^+^ T cells were enriched from spleens and lymph nodes by negative selection using MACS systems (Miltenyi Biotec, Auburn, CA) following the manufacturer's instructions. Freshly isolated total T cells with 75-80% CD3 positivity were either maintained in culture media with 5ng/ml IL7 or were stimulated with IL-2 (100U/ml) and plate-bound anti-CD3 (clone 145-2C11) and anti-CD28 (clone 37.51). Plates were pre-coated with 2 μg/ml antibodies overnight at 4°C. Cells were cultured in RPMI 1640 media supplemented with 10% (v/v) heat-inactivated fetal bovine serum (FBS), 2 mM L-glutamine, 0.05 mM *2-mercaptoethanol*, 100 units/ml penicillin and 100 μg/ml streptomycin at 37 °C in 5% CO2. For CFSE dilution analysis, cells were pre-incubated for 10 min in 4 μM CFSE (Invitrogen) in PBS plus 5% FBS before culture. For iT~reg~ cell differentiation, 0.5 x10^6^ naive CD4^+^ T cells were stained with 4 μM CFSE and cultured with 100 U/ml IL-2, 5ng/ml TGF-β and 20ng/ml IL-6 in 0.5ml RPMI-1640 media (containing 10% (v/v) heat-inactivated fetal bovine serum (FBS), 2 mM L-glutamine, 0.05 mM *2-mercaptoethanol*, 100 units/ml penicillin and 100 μg/ml streptomycin) in 48-well tissue culture plate that was pre-coated with 10µg/ml anti-CD3 and 10µg/ml anti-CD28 overnight at 4°C . For T~H~17 conditions, 0.5 x10^6^ naive CD4^+^ T cells and 5 x10^6^ irradiated splenocytes (artificial APC) were cultured with 2 μg/ml anti-CD3 (2C11; Bio X Cell), 2 μg/ml anti-CD28 (37.51; Bio X Cell), 8 μg/ml anti--IL-2, 8 μg/ml anti--IL-4, 8 μg/ml anti--IFN-γ, 2 ng/ml TGF-β, and 20-50ng/ml IL-6 in 1ml IMDM media (containing 15% (v/v) heat-inactivated fetal bovine serum (FBS), 2 mM L-glutamine, 0.05 mM *2-mercaptoethanol*, 100 units/ml penicillin and 100 μg/ml streptomycin) in 24-well tissue culture plate). For metabolic starvation experiment, Glucose or Glutamine-free IMDM and RPMI-1640 medium was supplemented with 10% (v/v) heat-inactivated dialyzed fetal bovine serum (DFBS). For T~H~17 rescue experiments, 0.5 x10^6^ naive CD4+ T cells were activated in complete IMDM medium. After 24 h cells were switched to conditional glutamine-free IMDM medium for 4 days. DFBS was made dialyzing against 100 volumes of distilled water (six changes in three days) using Slide-ALyzer G2 dialysis cassettes with cut-through MW size 2K (ThermoFisher Scientific) at 4⁰C.

qPCR and immunoblot analysis. {#s4-4}
-----------------------------

Total RNA was isolated using the RNeasy Mini Kit (Qiagen) and was reverse transcribed using random hexamer and M-MLV Reverse Transcriptase (Invitrogen). SYBR green-based quantitative RT-PCR was performed using the Applied Biosystems 7900 Real Time PCR System. The relative gene expression was determined by the comparative *C*~T~ method also referred to as the 2^−ΔΔ*C*^~T~ method. The data were presented as the fold change in gene expression normalized to an internal reference gene (beta2-microglobulin) and relative to the control (the first sample in the group). Fold change=2^−ΔΔ*C*^~T~=\[(*C*~Tgene\ of\ interst~- *C*~Tinternal\ reference~)\]sample A-=\[(*C*~Tgene\ of\ interst~- *C*~Tinternal\ reference~)\]sample B. Samples for each experimental condition were run in triplicated PCR reactions. Primer sequences were obtained from Primer Bank ([@bib97]). Primer sequences are listed in [Supplementary file 1](#supp1){ref-type="supplementary-material"}. Cell extracts were prepared and immunoblotted as previously described ([@bib107]).

MOG immunization and EAE {#s4-5}
------------------------

Mice were immunized with 100 μg of myelin oligodendrocyte glycoprotein (MOG)~35--55~ peptide in CFA (Difco) with 500 μg of Mycobacterium tuberculosis (Difco). Mice were i.p. injected 200 ng of pertussis toxin (List Biological,\#181) on the day of immunization and 2 days later, as described ([@bib44]). The mice were observed daily for clinical signs and scored as described previously ([@bib95]).

Histopathology and immunohistochemistry {#s4-6}
---------------------------------------

Mice were euthanized and then were perfused with 25 ml PBS with 2 mM EDTA by heart puncture to remove blood from internal organs. Spinal cords were taken out and fixed by immersion with 10% neutral buffered formalin solution and decalcified. Spinal column was divided into cervical, thoracic and lumbar, and then was embedded in paraffin, sectioned, and stained with standard histological methods for hematoxylin and eosin (H and E). Immunohistochemistry were performed on serial histological sections according to standard protocols using anti-Mac2 and anti-CD3 (1:50, Santa Cruz). Appropriate horseradish peroxidase (HRP)-conjugated secondary antibodies were used and detected using 3,3'-diaminobenzidine tetrahydrochloride (DAB). Slides were counterstained with hematoxylin. Microscopy images were taken using Zeiss Axio Scope A1.

Metabolic activity analysis {#s4-7}
---------------------------

Glutamine oxidation activity was determined by the rate of ^14^CO~2~ released from \[U-^14^C\]-glutamine ([@bib8]). In brief, one-five million T cells were suspended in 0.5 ml fresh media. To facilitate the collection of ^14^CO~2~, cells were dispensed into 7 ml glass vials (TS-13028, Thermo) with a PCR tube containing 50 μl 0.2M KOH glued on the sidewall. After adding 0.5 μci \[U-^14^C\]-glutamine, the vials were capped using a screw cap with rubber septum (TS-12713, Thermo). The assay was stopped 2 hr later by injection of 100 μl 5N HCL and the vials were kept at room temperate overnight to trap the ^14^CO~2~. The 50 μl KOH in the PCR tube was then transferred to scintillation vials containing 10 ml scintillation solution for counting. A cell-free sample containing 0.5 μci \[U-^14^C\]-glutamine was included as a background control.

Pyruvate oxidation activity was determined by the rate of ^14^CO~2~ released from \[2-^14^C\]-pyruvate ([@bib112]). In brief, one to five million T cells were suspended in 0.5 ml fresh T cell media. To facilitate the collection of ^14^CO~2~, cells were dispensed into 7 ml glass vials (TS-13028, Thermo) with a PCR tube containing 50 μl 0.2M KOH glued on the sidewall. After adding 0.5 μci \[2-^14^C\]-pyruvate, the vials were capped using a screw cap with rubber septum (TS-12713, Thermo). The assay was stopped 2 hr later by injection of 100 μl 5N HCL and the vials were kept at room temperate overnight to trap the ^14^CO~2~. The 50 μl KOH in PCR tube was then transferred to scintillation vials containing 10 ml scintillation solution for counting. A cell-free sample containing 0.5 μci \[2-^14^C\]-pyruvate was included as a background control.

Metabolite extraction and analysis by ion chromatography-ultra high resolution-Fourier transform mass spectrometry (IC-UHR-FTMS) {#s4-8}
--------------------------------------------------------------------------------------------------------------------------------

Cells were cultured in glutamine-free media with 2 mM ^13^C~5~^15^N~2~-glutamine (Cambridge Isotope Laboratories) for 24 hr at 37°C and were then washed three times in cold PBS before snap freezing. The frozen cell pellets were homogenized in 60% cold CH3CN in a ball mill (Precellys- 24, Bertin Technologies) for denaturing proteins and optimizing extraction. Polar metabolites were extracted by the solvent partitioning method with a final CH3CN:H2O:CHCl3 (2:1.5:1, v/v) ratio, as described previously ([@bib23]). The polar extracts were lyophilized before reconstitution in nanopure water and analysis on a Dionex ICS-5000 +ion chromatography interfaced to a Thermo Fusion Orbitrap Tribrid mass spectrometer (Thermo Fisher Scientific) as previously described ([@bib24]) using a *m/z* scan range of 80--700. Peak areas were integrated and exported to Excel via the Thermo TraceFinder (version 3.3) software package before natural abundance correction ([@bib67]). The isotopologue distributions of metabolites were calculated as the mole fractions as previously described ([@bib49]). The number of moles of each metabolite was determined by calibrating the natural abundance-corrected signal against that of authentic external standards. The amount was normalized to the amount of extracted protein, and is reported in µmol/g protein. Metabolome quantification of GSH and GSSG were determined by CE-MS that was carried out through a facility service at Human Metabolome Technology Inc., Tsuruoka, Japan.

Statistical analysis {#s4-9}
--------------------

*P* values were calculated with Student\'s *t*-test all experiment except EAE experiments, where two way anova test was performed. *P* values smaller than 0.05 were considered significant, with p-values\<0.05, p-values\<0.01, and p-values\<0.001 indicated as \*, \*\*, and \*\*\*, respectively.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Glutathione denovo synthesis coordinates with glutaminolysis to control redoxhomeostasis & directs Tcell differentiation\" for consideration by *eLife*. Your article has been reviewed by Tadatsugu Taniguchi as the Senior Editor, a Reviewing Editor, and three reviewers. The following individual involved in review of your submission has agreed to reveal his identity: Chi Van Dang (Reviewer \#2).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

You have investigated the role of glutathione (GSH) de novo biosynthesis during T cell activation and differentiation. Using mouse genetic models, you found that GSH de novo synthesis plays a critical role in T~H~17 differentiation but is less important for T~reg~ polarization. The defect in T~H~17 differentiation is due to the accumulation of ROS. Furthermore, loss of GSH reductase, the enzyme that reduces oxidized GSSG to GSH, does not have any effect on T cell differentiation. Finally, you have connected glutaminolysis, an important metabolic rewiring step in T cell differentiations, to GSH production. You have asked an interesting and important question and found an interesting answer to complement the discovery by Mak et al. (2017). These studies together elucidate the physiological role of glutathione synthesis in T cell differentiation. However, the reviewers felt there were still some conclusions that need to be strengthened for publication in *eLife*.

Essential revisions:

The reviewers would like to prioritize further data on how glutathione de novo biosynthesis/redox contributes to the biological effect of glutaminolysis in T cell differentiation:

1\) Can you rescue T~H~17 differentiation or suppress T~reg~ differentiation in the qlutamine free condition by mitigating the ROS through an anti-oxidant, such as NAC? Does pharmacological inhibition of the first step of glutaminolysis at glutaminase (via CB-839 or BPTES, which is documented to increase ROS) could skew away from T~H~17 toward T~reg~ differentiation.

2\) Can exogenous supply of other glutamine-derived metabolites (TCA cycle intermediate or nucleotide) rescue T~H~17 differentiation in glutamine-free condition without influencing the redox status?

3\) In Figure 6B, you claimed a glutamine-dependent flux into GSH, but M+5 species is minimal compared to the other species, while glutamine depletion causes very profound defect in T~H~17 in Figure 6D. You need to show the levels of GSH during glutamine starvation and should be more careful about conclusions on the significance of glutamine-dependent GSH production on T~H~17 differentiation.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

Thank you for sending your article entitled \"Glutathione de novo synthesis but not recycling process coordinates with glutaminolysis to control redox homeostasis and directs murine T cell differentiation\" for peer review at *eLife*. Your article is being evaluated by Tadatsugu Taniguchi as the Senior Editor, a Reviewing Editor, and three reviewers.

There was a diversity of opinion among reviewers and we invite you to respond within the next two weeks with an action plan and timetable to respond whether you will undertake below proposed revisions that require would appear to require new experiments within a two month period or do you disagree and prefer to move ahead with textual changes to address the essential and minor comments without new experiments. Based on your response we will then provide a decision letter. If you decide on the latter course it's very likely the result will be acceptable, but the editors wanted to leave the former option open to you given that you may see it as an opportunity you don\'t want to miss.

Essential revisions:

The question regarding rescue of glutamine-deprived T~H~17 cells with NAC or with downstream metabolites was only partially addressed. While you showed that hypoxanthine and thymidine could partially rescue T~H~17 without altered ROS, NAC alone could not rescue the phenotype. You missed the opportunity of combining hypoxanthine, thymidine and NAC to test your hypothesis that ROS plays a critical role. Further, your experiments using CB839, BPTES, and DON were not accompanied by any ROS measurements. Specifically, according to the T~H~-Express database, in contrast to your assertion, Gls is expressed across murine T cell subsets. Hence, the lack of effects of specific Gls inhibitors seem surprising. DON is a non-specific glutamine analog that has pleiotropic effects. ROS measurements would help overcome these concerns.

1\) Subsection "GCLC deficiency but not GCLM or GSR deficiency suppresses T cell activation and proliferation", why the authors concluded \"T cells are relatively resistant toward ferroptosis\", as I saw a modest reduction of viability.

2\) Subsection "Glutamate that fuels GSH de novo synthesis is partially derived from glutamine during T~H~17 cell differentiation", a simplest explanation of Figure 6B is that glutamine uptake in iT~reg~ is significantly lower. But whatever glutamine that cells can uptake, contributes similarly to glutamate and GSH between T~H~17 and iT~reg~.

3\) Subsection "Glutamate that fuels GSH de novo synthesis is partially derived from glutamine during T~H~17 cell differentiation", I understand that the assay has been widely used, but the fundamental rationale behind it is unclear. Because the carbon dioxide released from glutamine is from α-ketoglutarate to succinyl-CoA, a step downstream of the glutamate. I think the experiment proves that glutaminolysis is more active in T~H~17 than iT~reg~ but cannot further justify the contribution of glutamine oxidation to GSH production.

10.7554/eLife.36158.029

Author response

> Essential revisions:
>
> The reviewers would like to prioritize further data on how glutathione de novo biosynthesis/redox contributes to the biological effect of glutaminolysis in T cell differentiation:
>
> 1\) Can you rescue T~H~17 differentiation or suppress T~reg~ differentiation in the qlutamine free condition by mitigating the ROS through an anti-oxidant, such as NAC?

We are thankful for the reviewer's thoughtful assessment and suggestion. We have performed the differentiation experiment to evaluate the effect of NAC on rescuing T~H~17 differentiation in glutamine free condition. We found that NAC treatment was incapable of rescuing T~H~17 differentiation (Figure 6---figure supplement 1F). NAC addition also failed to restore cell proliferation in the absence of glutamine as indicated by comparable low cell numbers in both groups (Figure 6---figure supplement 1G). On the other hand, our conclusion is that GSH de novo biosynthesis requires glutamine-derived glutamate as precursor and plays a critical role in regulating ROS homeostasis during T~H~17 cell differentiation. We apologize if we have given the unintended impression that GSH de novo biosynthesis is responsible for all essential functions of glutaminolysis. Other glutamine-derived metabolites, as the reviewer pointed out below, also play significant roles in driving T cell proliferation, maintaining cell viability and regulating T cell differentiation. We ensured that this is stated clearly in the text.

> Does pharmacological inhibition of the first step of glutaminolysis at glutaminase (via CB-839 or BPTES, which is documented to increase ROS) could skew away from T~H~17 toward T~reg~ differentiation.

We are thankful for the reviewer's insightful suggestion. Glutaminase (GLS) (Altman et al. 2016) is a rate-limiting enzyme in glutamine catabolic pathway. Assessing the impact of GLS inhibitors in modulating T cell differentiation will not only provide mechanistic insights and also provide useful information that may have the potential to direct clinical application in the future. As the reviewer suggested, we have examined T~H~17 and iT~reg~ differentiation in the presence of CB-839 or BPTES, two recently developed GLS inhibitors that preferentially inhibit GLS1 (Wang et al. 2010, Le et al. 2012). In addition, we also include 6-diazo-5-oxo-l-norleucine (DON), an analog of glutamine with broad inhibitory effects glutamine utilizing enzymes (Pinkus 1977, Shapiro et al. 1979), since our previous study indicated that GLS2 is significantly induced following T cell activation (Wang et al. 2011). Our results showed that DON treatment significantly suppressed T~H~17 cell differentiation (Figure 6---figure supplement 1D). Instead, BPTES or CB-839 treatment slightly enhanced IL-17A expression (Figure 6---figure supplement 1D). In line with these data, DON but not BPTES or CB-839 treatment significantly enhanced ROS production under T~H~17-polarizing condition (Figure 6---figure supplement 1E).

> 2\) Can exogenous supply of other glutamine-derived metabolites (TCA cycle intermediate or nucleotide) rescue T~H~17 differentiation in glutamine-free condition without influencing the redox status?

We share a similar thought on the relevance of other glutamine-derived metabolites with the reviewers. Glutamine catabolism is not only coupled to the de novo synthesis of GSH, but also generates the anaplerotic substrate, α-ketoglutarate (α-KG), and substrates for nucleotide biosynthesis. As the reviewer pointed out, it is important to assess the contribution of α-KG and nucleotide in T~H~17 cell's glutamine dependency. Therefore, we have supplied T cells with either α-KG and or hypoxanthine + thymidine (HT) under glutamine free condition and assessed T cell differentiation and ROS. Our data showed that the addition of either HT or α-KG was able to partially rescue T~H~17 differentiation in glutamine-free condition without impacting ROS level (Figure 6F and 6G). These results clearly demonstrated that other glutamine-derived metabolites, including nucleotides and α-KG contribute to T~H~17 cells' glutamine dependency independent of ROS regulation. Again, we apologize if we have given the impression that GSH de novo biosynthesis is responsible for all essential functions of glutaminolysis. We ensured that this is stated clearly in the text.

> 3\) In Figure 6B, you claimed a glutamine-dependent flux into GSH, but M+5 species is minimal compared to the other species, while glutamine depletion causes very profound defect in T~H~17 in Figure 6D. You need to show the levels of GSH during glutamine starvation and should be more careful about conclusions on the significance of glutamine-dependent GSH production on T~H~17 differentiation.

We apologize for giving the impression of overstating our data and have adjusted the text to properly explain our data. We also agree with the reviewer's assessment on M+5 species data and appreciate the reviewer's constructive comment on including GSH data following glutamine starvation. We have now included the data showing that, glutamine starvation reduced GSH content in a time-dependent manner in T~H~17 cells (Figure 6---figure supplement 1A). In addition, we have optimized the experimental conditions in assessing glutamine metabolic flux using ^13^C-tracer. In addition, we have included iT~reg~ cells group as a comparison of T~H~17 cells (Figure 6B). Our data revealed that T~H~17 cells displayed a higher capacity of funneling glutamine-derived carbons to glutamate and GSH than iT~reg~ cells, as indicated by significantly elevated quantity of ^13^C~5~ labelled glutamate and GSH (Figure 6B, upper panel). Moreover, a significant portion of GSH pool comes from ^13^C~5~-GSH, indicative of a direct conversion of ^13^C-glutamine into GSH (Figure 6B, lower panel).

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

> Essential revisions:
>
> The question regarding rescue of glutamine-deprived T~H~17 cells with NAC or with downstream metabolites was only partially addressed. While you showed that hypoxanthine and thymidine could partially rescue T~H~17 without altered ROS, NAC alone could not rescue the phenotype. You missed the opportunity of combining hypoxanthine, thymidine and NAC to test your hypothesis that ROS plays a critical role. Further, your experiments using CB839, BPTES, and DON were not accompanied by any ROS measurements. Specifically, according to the Th-Express database, in contrast to your assertion, Gls is expressed across murine T cell subsets. Hence, the lack of effects of specific Gls inhibitors seem surprising. DON is a non-specific glutamine analog that has pleiotropic effects. ROS measurements would help overcome these concerns.

We thank the reviewers for the additional constructive comments. We took this opportunity to further strengthen our studies by performing additional experiments and properly interpreting our data.

Specifically,

1\) We have assessed T~H~17differentiation in glutamine-starvation condition after adding HT and NAC either alone or in combination. While NAC alone is insufficient to support T~H~17differentiation (likely due to its incapability of supporting T cell proliferation in the absence of glutamine), the combination of NAC and HT resulted in more differentiated T~H~17cells and lower level of ROS comparing to HT alone in the absence of glutamine (Figure 6---figure supplement 1F and G). These results support the idea that glutamine catabolism supports T~H~17differentiation through providing precursors for supporting both proliferation and redox regulation.

2\) For CB839, BPTES, and DON experiment, we have included original ROS data (Figure 6---figure supplemental 1E). We found that only DON treatment increases ROS production, which is in consistent with our T~H~17differentiation data (only DON suppresses T~H~17differentiation). Now, we include both histogram and bar-graph in our revised figure. We also thank the reviewer for pointing out the expression data of Gls1 extracted from T~H~-Express database. We apologize for giving the impression that Gls1 is not expressed in CD4^+^ T cells. We agree with the reviewer's assessment on the pleiotropic effects of DON. We now carefully revised our interpretation on the data. In addition to Gls1, we reasoned that Gls2 may compensate for the inhibition of Gls1. Gls2 is also expressed in all T cell subsets with the highest expression level in T~H~17subset based on T~H~-Express database, and the protein level of Gls2 has been shown to be induced following T cell activation (Wang, Dillon et al., 2011). We also speculated that other glutamine utilizing enzymes including amidotransferase could convert glutamine into glutamate and might be involved in supporting GSH biosynthesis in T cells.

> 1\) Subsection "GCLC deficiency but not GCLM or GSR deficiency suppresses T cell activation and proliferation", why the authors concluded \"T cells are relatively resistant toward ferroptosis\", as I saw a modest reduction of viability.

We agree with the reviewer's assessment and have rephrased our interpretation according to the suggestion.

> 2\) Subsection "Glutamate that fuels GSH de novo synthesis is partially derived from glutamine during T~H~17 cell differentiation", a simplest explanation of Figure 6B is that glutamine uptake in iT~reg~ is significantly lower. But whatever glutamine that cells can uptake, contributes similarly to glutamate and GSH between T~H~17 and iT~reg~.

We thank the reviewer for this insightful comment and have now included the heightened glutamine update as a possible explanation of our data.

> 3\) Subsection "Glutamate that fuels GSH de novo synthesis is partially derived from glutamine during T~H~17 cell differentiation", I understand that the assay has been widely used, but the fundamental rationale behind is unclear. Because the carbon dioxide released from glutamine is from α-ketoglutarate to succinyl-CoA, a step downstream of the glutamate. I think the experiment proves that glutaminolysis is more active in T~H~17 than iT~reg~ but cannot further justify the contribution of glutamine oxidation to GSH production.

We apologize for giving the impression of overstating our data and have adjusted the text to properly explain our data according to the reviewer's comment. Specifically, we have now highlighted the possibility that the overall uptake and consumption of glutamine, including oxidation of glutamate through the TCA cycle and utilization of glutamate for GSH biosynthesis is enhanced in T~H~17 comparing to iT~reg~ cells.

We thank the editor and all of the assigned reviewers for the time and effort involved in assessing our work, and we hope that the reviewer agrees that in addressing the concerns we have substantially improved our manuscript.

[^1]: These authors contributed equally to this work.
